Steven G. Coca, DO, BRCU Faculty
Steven G. Coca, DO, is a graduate of the University of New England College of Osteopathic Medicine. He completed his medical residency and clinical nephrology fellowship at Yale University and Yale New Haven Hospital in Connecticut. He also received a Master’s Degree in Epidemiology and Public Health during his training at Yale. There, he later served as an Assistant Professor in the Section of Nephrology, and currently is an Associate Professor of Medicine at Icahn School of Medicine at Mount Sinai.
Dr. Coca has been an active investigator in three large NIH-funded consortiums: the Translational Research in Biomarker Endpoints in Acute Kidney Injury (TRIBE-AKI) consortium; the Assessment, Serial Evaluation, and Subsequent Sequelae in Acute Kidney Injury (ASSESS-AKI) consortium; and the CKD Biomarkers Consortium. Dr. Coca is also the principal investigator of an ancillary study to the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial and a member of the newly formed Drug Development Tools for Kidney Disease (DDT-KD) Consortium, sponsored by the Critical Path Institute. His major research areas include using newer biomarkers to aide risk-stratification for outcomes in acute kidney injury and chronic kidney disease. His major clinical interests include AKI, CKD, electrolyte disorders, hypertension, and cardiorenal syndrome.